Certified license assays are developed by trusted partners who have in-licensed our biomarker technology. These assays are ensuring regulatory compliance and clinical availability on a broad menu of…
Proprietary biomarker assays are developed in-house by SphingoTec, utilizing our exclusive biomarkers and scientific expertise. These high-quality assays are available for research use only,…
The sphingotest® Lightning is a reagent intended for research use only and used for automated chemiluminescence measurement of sphingotest® immunoluminometric assays (ILMA) using acridinium ester…
Proenkephalin A 119–159 (penKid) has been successfully integrated into daily practice in intensive care unit (ICU), demonstrating its effectiveness in assessing kidney function and predicting acute…
Results from the first prospective study, conducted at the Medical University of Vienna, demonstrating penKid as a discriminatory biomarker for successful liberation from CRRT in cardiac surgery…
Through this collaboration, the companies will bring an assay for SphingoTec’s innovative kidney function biomarker, Proenkephalin 119-159 (penKid), to Beckman Coulter’s extensive test menu for use…
SphingoTec announces the successful closing of a Series C financing round. The raised capital will allow the company to reach profitability through sustained and strategic commercialization of its…
SphingoTec introduced together with Boditech Med Inc. (Boditech) at the 42nd AKI & CRRT Course in Vicenza the innovative kidney function biomarker penKid developed by SphingoTec and licensed to…
